Q3 2024 Holdings
Filed 2024-11-13 | 11 holdings | $498.7M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Arcellx, Inc.(ACLX) | Common Stock | 03940C100 | $196.0M | 2,346,630 | 39.3% |
| Zenas BioPharma, Inc(ZBIO) | Common Stock | 98937L105 | $83.1M | 4,911,539 | 16.7% |
| ARS Pharmaceuticals, Inc.(SPRY) | Common Stock | 82835W108 | $58.2M | 4,012,903 | 11.7% |
| Crispr Therapeutics AG(CRSP) | Common Shares | H17182108 | $49.3M | 1,048,951 | 9.9% |
| Design Therapeutics, Inc.(DSGN) | Common Stock | 25056L103 | $35.1M | 6,526,476 | 7.0% |
| Mineralys Therapeutics Inc.(MLYS) | Common Stock | 603170101 | $24.4M | 2,016,822 | 4.9% |
| Alumis Inc.(ALMS) | Common Stock | 022307102 | $20.9M | 1,959,896 | 4.2% |
| Nkarta, Inc.(NKTX) | Common Stock | 65487U108 | $15.1M | 3,333,333 | 3.0% |
| Oruka Therapeutics, Inc(ORKA) | Common Stock | 687604108 | $9.2M | 375,330 | 1.8% |
| enGene Holdings Inc.(ENGN) | Common Shares | 29286M105 | $4.9M | 747,750 | 1.0% |
| Kala Bio, Inc.(KALA) | Common Stock | 483119202 | $2.5M | 443,661 | 0.5% |